polatuzumab vedotin
roche
['bet', 'dlbcl', ' ipi ', ' pola ', 'polatuzumab', 'lymsm']
post-car-t dlbcl progression divided into four groups: chemotherapy, bispecific antibodies, checkpoint inhibitors or polatuzumab-br - those receiving pola-br did marginally better, notably some durable responses in each group #ash22 #lymsm 
haematology registrar | fellow @PORTAL_research @harvardmed |
evidence-based medicine | health policy | lymphoma | myeloma |
Fulbright scholar | muso | writer